Schering-Plough’s Cholesterol Franchise Holds 16.4 Percent Of New Scripts
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales of Vytorin and Zetia climb 48 percent to $1.2 billion during the first quarter.
You may also be interested in...
Schering-Plough/Merck File Claritin, Singulair Combination
NDA has been accepted by FDA for a standard 10-month review.
Schering-Plough/Merck File Claritin, Singulair Combination
NDA has been accepted by FDA for a standard 10-month review.
Schering-Plough And Merck Plan Zetia/Lipitor Combination Following Patent Expiry
Ezetimibe/atorvastatin combination is intended as a complement to Vytorin, Schering-Plough says.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: